Accuracy of frozen section diagnosis at surgery in pre- malignant and malignant lesions of the endometrium

Objective: The purpose of this study was to correlate the histological diagnosis made during intraoperative frozen section examination of hysterectomies with atypical hyperplasia or carcinoma, with the definitive paraffin section histology. Study Design: Frozen section pathology results of patients with a preoperative biopsy showing atypical hyperplasia or endometrial carcinoma (87 patients) were compared retrospectively with paraffin section pathology findings. Those patients with curettage specimens showing atypical hyperplasia or curettings suspicious of endometrioid carcinoma had intraoperative frozen section to determine whether an invasive lesion was present and whether they required pelvic lymphadenectomy. The purpose of frozen section assessment in those patients who had a preoperative curettage specimen showing endometrial carcinoma was to identify poor prognostic pathological factors related to histological subtype, grade, depth of myometrial invasion and cervical involvement. Results: The correlation between frozen sections and paraffin histology in patients with endometrial carcinoma was 98.6% (69/70) for histological sub-type and 84.3% (59/70) for grade of differentiation. Depth of myometrial invasion was accurately diagnosed in 94.3% (66/70) while cervical involvement was accurately assessed in 86.7% (52/60). Of the 37 patients with atypical hyperplasia or suspicious curettings on preoperative curettage who had intraoperative frozen section, 23 patients had invasive malignancy, which was confirmed in subsequent paraffin sections. Of the remaining 14 patients with a non-malignant frozen section diagnosis, 11 were confirmed with paraffin sections while three had a small well differentiated invasive lesion, two were FIGO Stage 1a and one had microscopic invasion into the myometrium. Conclusion: Intraoperative frozen section is a useful procedure to identify poor prognostic pathological factors as well as to diagnose endometrial cancer in patients undergoing hysterectomy for a preoperative biopsy diagnosis of atypical hyperplasia.

Frozen section; Endometrial carcinoma; Endometrial hyperplasia

[1] Jemal A., Tiwari R.C., Murray T., Ghafour A., Samuels A., Ward E. et al.: “Cancer Statistics, 2004”. CA Cancer J. Clin., 2004, 54, 8.

[2] Cooper N.: “Cancer Atlas of the UK and Ireland 1991-2000”. Chapter 23; 239. Office for National Statistics Publication.

[3] Fisher B., Constantino J.P., Redmond C.K., Fisher E.R., Wickerham D.L., Cronin W.M.: “Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project B-14”. J. Natl. Cancer Inst., 1994, 86, 527.

[4] Assikis V.J., Neven P., Jordan V.C., Vergote I.: “A realistic clinical perspective on tamoxifen and endometrial carcinogenesis”. Eur. J. Cancer, 1996, 32A, 1464.

[5] Kurman R.J., Kaminski P.F., Norris H.J.: “The behaviour of endometrial hyperplasia: a long-term study of ‘untreated’ hyperplasia in 170 patients”. Cancer, 1985, 56, 403.

[6] Silverberg S.G.: “Hyperplasia and carcinoma of the endometrium”. Semin. Diagn. Pathol., 1988, 135.

[7] Huang S.J., Amparo E.G., Yu Y.S.: “Endometrial hyperplasia: histologic classification and behaviour”. Surg. Pathol., 1988, 1, 215.

[8] Widra E.A., Dunton C.J., McHugh M., Palazzo J.P.: “Endometrial hyperplasia and the risk of carcinoma”. Int. J. Gynaecol. Cancer, 1995, 5, 233.

[9] Ferenczy A., Gelfand M.: “The biologic significance of cytologic atypia in progestin treated endometrial hyperplasia”. Am. J. Obstet. Gynaecol., 1989, 160, 126.

[10] Kurman R.J., Norris H.J.: “Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma”. Cancer, 1982, 49, 2547.

[11] Janicek M.F., Rosenshein N.B.: “Invasive endometrial cancer in uteri resected for atypical endometrial hyperplasia”. Gynaecol. Oncol., 1994, 52, 373.

[12] Kilgore L.C., Partridge E.E., Alvarez R.D., Austin J.M., Shingleton H.M., Noojin F. et al.: “Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling”. Gynaecol. Oncol., 1995, 56, 29.

[13] “ASTEC: A Study in the Treatment of Endometrial Cancer”. MRC Clinical Trials Unit, version 3, 2003.

[14] Kent Cancer Centre Protocol for the treatment of endometrial cancer. Guidelines Network and Treatment Group 2005.

[15] Mohan D.S., Samuels M.A., Selim M.A., Shalodi A.D., Ellis R.J., Sameuls J.R. et al.: “Long-term outcomes of therapeutic pelvic lymphadenectomy for Stage I endometrial adenocarcinoma”. Gynaecol. Oncol., 1998, 70, 165.

[16] COSA-NZ-UK Endometrial Cancer Study Groups: “Pelvic lymphadenectomy in high-risk endometrial cancer”. Int. J. Gynaecol. Cancer, 1996, 6, 102.

[17] Orr J.W., Holimon J.L., Orr P.F.: “Stage I corpus cancer: is teletherapy necessary”. Am. J. Obstet. Gynecol., 1997, 176, 777.

[18] Fanning J.: “Long-term survival of intermediate risk endometrial cancer (Stage IG3, IC, II) treated with full lymphadenectomy and brachytherapy without teletherapy”. Gynaecol. Oncol., 2001, 82, 371.

[19] Seago D.P., Raman A., Lele S.: “Potential benefit of lymphadenectomy for the treatment of node negative locally advanced uterine cancers”. Gynecol. Oncol., 2001, 83, 282.

[20] Horowitz N.S., Peters W.A., Smith M.R., Drescher C.W., Atwood M., Mate T.P.: “Adjuvant high dose rate vaginal brachytherapy as treatment of Stage I and II endometrial cancer”. Obstet. Gynaecol., 2002, 99, 235.

[21] Quinlivan J.A., Petersen R.W., Nicklin J.L.: “Accuracy of frozen section for the operative management of endometrial cancer”. Br. J. Obstet. Gynaecol., 2001, 108, 798.

[22] Zorlu C.G., Kuscu E., Ergun Y., Aydogdu T., Cobanoglu O., Erdas O.: “Intraoperative evaluation of prognostic factors in Stage I endometrial cancer by frozen section: how reliable?”. Acta Obstet. Gynaecol. Scand., 1993, 72, 382.

[23] Badia J., Chuaqui R., Hamed F., Wild R., Barrena N., Mayerson D., Oyarzun E.: “An intraoperative anatomicopathological study of myometrial penetration in endometrial cancer: its usefulness in making decisions on extending the primary surgical treatment”. Rev. Chil. Obstet. Ginecol., 1992, 57, 420.

[24] Kayikcioglu F., Boran N., Meydanli M.M., Tulunay G., Kose F.M., Bulbul D.: “Is frozen section diagnosis a reliable guide in surgical treatment of Stage I endometrial cancer?”. Acta Oncol., 2002, 41, 444.

[25] Kir G., Kir M., Cetiner H., Karateke A., Gurbuz A.: “Diagnostic problems on frozen section examination of myometrial invasion in patients with endometrial carcinoma”. Eur. J. Gynaecol. Oncol., 2004, 25, 211.

[26] Homesley H.D., Boike G., Spiegel G.W.: “Feasibility of laparoscopic management of presumed Stage I endometrial carcinoma and assessment of accuracy of myoinvasion estimates by frozen section: a gynecologic oncology group study”. Int. J. Gynecol. Cancer, 2004, 14, 341.

[27] Malviya V.K., Deppe G., Malone J.M., Sundareson A.S., Lawrence W.D.: “Reliability of frozen section examination in identifying poor prognostic indicators in Stage I endometrial adenocarcinoma”. Gynecol. Oncol., 1989, 34, 299.

[28] Frumovitz M., Slomovitz B.M., Singh D.K., Broaddus R.R., Abrams J., Sun C.C., Bevers M., Bodurka D.C.: “Frozen section analyses as predictors of lymphatic spread in patients with early stage uterine cancer”. J. Am. Coll. Surg., 2004, 199, 388.

[29] Kucera E., Kainz C., Reinthaller A., Sliutz G., Leodolter S., Kucera H., Breitenecker G.: “Accuracy of intraoperative frozen section diagnosis in Stage I endometrial adenocarcinoma”. Gynecol. Obstet. Inv., 2000, 49, 62.

[30] Fanning J., Tsukada Y., Piver M.S.: “Intraoperative frozen section diagnosis of depth of myometrial invasion in endometrial adenocarcinoma”. Gynecol. Oncol., 1990, 37, 47.

[31] Shim J.U., Rose P.G., Reale F.R., Soto H., Tak W.K., Hunter R.E.: “Accuracy of frozen section diagnosis at surgery in clinical Stage I and II endometrial carcinoma”. Am. J. Obstet. Gynecol., 1992, 166, 1335.

[32] Obermair A., Geramou M., Gucer F., Denison U., Kapshammer E., Medl M. et al.: “Endometrial cancer: accuracy of the finding of a well differentiated tumour at dilatation and curettage compared to the findings at subsequent hysterectomy”. Int. J. Gynecol. Cancer, 1999, 9, 383.

[33] Petersen R.W., Quinlivan J.A., Casper G.R., Nicklin J.L.: “Endometrial adenocarcinoma - presenting pathology is a poor guide to surgical management”. Aust NZ J. Obstet. Gynaecol., 2000, 40, 191.

[34] Manfredi R., Mirk P., Maresca G., Margariti P.A., Testa A., Zannoni G.F., Giordano D., Scambia G., Marano P.: “Local regional staging of endometrial carcinoma: role of MRI in surgical planning”. Radiology, 2004, 231, 372.

[35] Shibutani O., Joja I., Shiraiwa M., Asakawa T., Miyagi Y., Kudo T., Hiraki Y.: “Endometrial carcinoma: efficacy of thin section oblique axial MR images for evaluating cervical invasion”. Abdom Imaging, 1999, 24, 520.

[36] Cunha T.M., Felix A., Cabral I.: “Preoperative assessment of deep myometrial and cervical invasion in endometrial carcinoma: comparison of MRI and gross visual inspection”. Int. J. Gynecol. Cancer, 2001, 11, 130.

[37] Frei K.A., Kinkel K.: “Staging endometrial cancer: role of MRI. Review article”. J. MRI, 2001, 13, 850.